1. Home
  2. SNDX vs CMRE Comparison

SNDX vs CMRE Comparison

Compare SNDX & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • CMRE
  • Stock Information
  • Founded
  • SNDX 2005
  • CMRE 1974
  • Country
  • SNDX United States
  • CMRE Monaco
  • Employees
  • SNDX N/A
  • CMRE N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • CMRE Marine Transportation
  • Sector
  • SNDX Health Care
  • CMRE Consumer Discretionary
  • Exchange
  • SNDX Nasdaq
  • CMRE Nasdaq
  • Market Cap
  • SNDX 1.1B
  • CMRE 1.3B
  • IPO Year
  • SNDX 2016
  • CMRE 2010
  • Fundamental
  • Price
  • SNDX $16.24
  • CMRE $11.75
  • Analyst Decision
  • SNDX Strong Buy
  • CMRE Hold
  • Analyst Count
  • SNDX 10
  • CMRE 1
  • Target Price
  • SNDX $37.50
  • CMRE $13.00
  • AVG Volume (30 Days)
  • SNDX 2.9M
  • CMRE 608.3K
  • Earning Date
  • SNDX 08-04-2025
  • CMRE 07-31-2025
  • Dividend Yield
  • SNDX N/A
  • CMRE 3.92%
  • EPS Growth
  • SNDX N/A
  • CMRE N/A
  • EPS
  • SNDX N/A
  • CMRE 2.37
  • Revenue
  • SNDX $77,933,000.00
  • CMRE $2,085,912,000.00
  • Revenue This Year
  • SNDX $434.67
  • CMRE N/A
  • Revenue Next Year
  • SNDX $108.62
  • CMRE N/A
  • P/E Ratio
  • SNDX N/A
  • CMRE $4.33
  • Revenue Growth
  • SNDX 2126.66
  • CMRE 56.37
  • 52 Week Low
  • SNDX $8.58
  • CMRE $6.02
  • 52 Week High
  • SNDX $22.50
  • CMRE $11.85
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 79.83
  • CMRE 73.13
  • Support Level
  • SNDX $15.36
  • CMRE $10.95
  • Resistance Level
  • SNDX $16.33
  • CMRE $11.32
  • Average True Range (ATR)
  • SNDX 0.78
  • CMRE 0.36
  • MACD
  • SNDX 0.31
  • CMRE 0.04
  • Stochastic Oscillator
  • SNDX 96.87
  • CMRE 95.67

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About CMRE Costamare Inc. $0.0001 par value

Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.

Share on Social Networks: